Objective: We developed an autologous, novel human blood-derived scaffold (hBDS) to improve pelvic floor disorders. Both Methods and Materials: After preparing the scaffold, it was xenotransplanted subcutaneously, and Results: Three days after implantation, no infection or severe inflammation was observed, and the scaffold was surrounded by connective tissue and fibroblasts, indicating initial scaffold degradation. By 1 week, the scaffold exhibited high biodegradation and increased fibroblast infiltration. Scaffold degradation was extensive at 2 weeks, with continued fibroblast infiltration and new collagen deposition. By 3 weeks, the scaffold had completely degraded, with minimal inflammation. The normal dermal structure was restored by weeks four to six after transplantation. Immunohistochemistry confirmed the neovascularization at one- and 2-week post- transplantation. Suturing the scaffold on the peritoneum and back muscle resulted in higher fibroblast infiltration and collagen formation around the suture compared to the non-suture group, with no morphological differences between the abdominal wall and back muscle reactions. Conclusion: The novel human blood-derived scaffold demonstrated biodegradation and high biocompatibility. Suturing the scaffold on the abdominal wall or back muscle effectively improves clinical symptoms, while further improvements are needed for its clinical application.